The present invention relates to fusion proteins comprising a non-cytotoxic protease and a EGF mutein ligand. The EGF mutein provides improved EGF receptor activation for the claimed fusion proteins. Also provided is the use of said polypeptides as therapeutics for suppressing mucus hypersecretion, inflammation, endocrine neoplasia and/or neuroendocrine disorders, neuroendocrine tumors, for suppressing cancers such as colorectal cancer, prostate cancer, breast cancer, and lung cancer.

Cossins; Aimee

Birch-Machin; Ian

Stancombe; Patrick

Syntaxin Limited

Non-cytotoxic fusion proteins comprising EGF muteins

The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumor cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalized and inhibits secretion from said tumor cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.

neuroendocrine tumors/protease

Non-cytotoxic fusion proteins comprising EGF muteins

Suppression of neuroendocrine diseases

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم